CD8A and neoplasm: Furthermore, a selective elimination of Gr-1+ CD11b+ MDSCs was induced by gemcitabine administered in minimal doses in mouse cancer models, leading to an improved activation of CD8+ T cells and NK cells along with an increased anti-tumor immunity [60].